NASDAQ:GERN - Geron Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.09 0.00 (0.00 %)
(As of 01/18/2019 06:38 AM ET)
Previous Close$1.09
Today's Range$1.07 - $1.12
52-Week Range$0.95 - $6.99
Volume657,900 shs
Average Volume2.74 million shs
Market Capitalization$203.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.07 million
Book Value$0.65 per share

Profitability

Net Income$-27,910,000.00
Net Margins-3,077.78%

Miscellaneous

Employees18
Market Cap$203.12 million
OptionableOptionable

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.22 million. Geron had a negative net margin of 3,077.78% and a negative return on equity of 19.16%. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

4 equities research analysts have issued twelve-month target prices for Geron's stock. Their predictions range from $1.50 to $7.00. On average, they anticipate Geron's share price to reach $3.5750 in the next year. This suggests a possible upside of 228.0% from the stock's current price. View Analyst Price Targets for Geron.

What is the consensus analysts' recommendation for Geron?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Has Geron been receiving favorable news coverage?

News coverage about GERN stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Geron earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

Are investors shorting Geron?

Geron saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 35,699,111 shares, an increase of 2.2% from the December 14th total of 36,502,581 shares. Based on an average daily volume of 4,504,534 shares, the short-interest ratio is currently 7.9 days. Currently, 19.3% of the shares of the stock are short sold. View Geron's Current Options Chain.

Who are some of Geron's key competitors?

Who are Geron's key executives?

Geron's management team includes the folowing people:
  • Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
  • Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
  • Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
  • Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)

Who are Geron's major shareholders?

Geron's stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.10%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

Which institutional investors are buying Geron stock?

GERN stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.09.

How big of a company is Geron?

Geron has a market capitalization of $203.12 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

What is Geron's official website?

The official website for Geron is http://www.geron.com.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]


MarketBeat Community Rating for Geron (NASDAQ GERN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  590
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel